Compare Amgen, Inc. (AMGN) vs CarMax, Inc (KMX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs CarMax, Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while CarMax, Inc trades at $53.68 (market cap $7.59B). The key difference: Amgen, Inc. is far larger — about 25.8× CarMax, Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals.
| AMGN | KMX | |
|---|---|---|
Market Cap | $196.12B | $7.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $65.20 |
52-Week Low | $271.18 | $30.88 |
Enterprise Value | $241.41B | $26.10B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
CarMax (KMX) trades at $53.49, up 4.86% with a bullish technical signal. The stock shows mixed fundamentals with a P/E of 33.22 and net margin of 0.84%, though recent Q1 2026 earnings beat expectations. Revenue trends downward from $31.9B in 2022 to $26.4B in 2025, while net cash flow turned negative at -$290M. Analyst sentiment is cautious with 62.9% hold ratings and a $48.91 consensus target below current price. Recent news highlights a four-pillar turnaround strategy under new CEO Keith Barr.
KMX presents a speculative opportunity amid transition, with potential upside from execution of digital and cost initiatives. Key risks include margin pressure, high debt load ($18.1B long-term), and investigation concerns. Near-term resistance at $53, support at $49. Wall Street remains neutral pending clearer turnaround evidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
